Company Overview
Snapshot
Founded in November 2020 by Assaf Bivas, ODE Pharma operates with 1–10 employees. The company has raised $1.5M across one funding round from Pollen Group Israel. In November 2024, ODE Pharma secured seed funding from Pollen Group Israel.
Business overview
ODE Pharma is a biotechnology company focused on developing treatments for respiratory and pulmonary disorders. The company leverages the body's natural systems, specifically the gut microbiome and mitochondria, to advance healthcare. Its core product, ODE-001, is designed to enable cell restoration and regeneration, strengthen cells, and reduce inflammation, with potential applications in treating multiple respiratory and gastrointestinal diseases. ODE Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In August 2024, ODE Pharma garnered attention for its research into the potential of papaya to treat cystic fibrosis in children. This highlights the company's innovative approach to leveraging natural compounds for therapeutic development and signals a potential expansion of its pipeline beyond its primary focus on ODE-001, indicating a broader strategic vision for addressing significant medical needs.
Log in to access full profile ›Company Intelligence Q&A
- What is ODE Pharma's primary focus?
- ODE Pharma is a biotechnology company dedicated to developing innovative treatments for respiratory and pulmonary disorders by harnessing the body’s natural systems, including the gut microbiome and mitochondria.
- When was ODE Pharma founded and by whom?
- ODE Pharma was founded in November 2020 by Assaf Bivas.
- What is ODE-001?
- ODE-001 is a product currently under development by ODE Pharma that aims to enable cell restoration and regeneration, strengthen cells, and reduce inflammation. It has potential indications for multiple respiratory and gastrointestinal diseases.
- What recent research has ODE Pharma been involved in?
- In August 2024, ODE Pharma's research into the potential of papaya to treat cystic fibrosis in children was highlighted, showcasing the company's innovative approach to therapeutic development.